Ineffectiveness of rabies vaccination alone for post-exposure protection against rabies infection in animal models

Antiviral Research

Volumn 135, Issue , 2016, Pages 56-61

  Zhang, Yi ^a   Zhang, Shoufeng ^b   Li, Lietao ^a   Hu, Rongliang ^b   Lin, Haixiang ^a   Liu, Hua ^a   Liu, Fang ^a   Shao, Hui ^a   Liu, Yuan ^a  

^a Yisheng Biopharma Co   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Adjuvant; Challenge; Post exposure prophylaxis; Post exposure therapy; Protection; Rabies vaccine

Indexed keywords

RABIES IMMUNOGLOBULIN; RABIES VACCINE; IMMUNOLOGICAL ADJUVANT; VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG SCREENING; DRUG TREATMENT FAILURE; FEMALE; KUNMING MOUSE; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; SYRIAN HAMSTER; VACCINATION; WILD TYPE; ANIMAL; BLOOD; DISEASE MODEL; DOG; HAMSTER; HUMAN; IMMUNOLOGY; MESOCRICETUS; SURVIVAL ANALYSIS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MESOCRICETUS; MICE; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; RABIES VIRUS; SURVIVAL ANALYSIS; VACCINATION; VACCINE POTENCY;

EID: 84991810171     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.10.002     Document Type: Article

References (21)

1. Bahloul, C., Ahmed, S.B., B'Chir, B.I., Kharmachi, H., Hayouni el, A., Dellagi, K., Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 22 (2003), 177–184.
2. Barkhouse, D.A., Faber, M., Hooper, D.C., Pre- and post-exposure safety and efficacy of attenuated rabies virus vaccines are enhanced by their expression of IFNgamma. Virology 474 (2015), 174–180.
3. Cliquet, F., Aubert, M., Sagne, L., Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 212 (1998), 79–87.
4. Coleman, P.G., Dye, C., Immunization coverage required to prevent outbreaks of dog rabies. Pediatr. Infect. Dis. J. 17 (1996), 261–263.
5. Gai, W.W., Zhang, Y., Zhou, D.H., Chen, Y.Q., Yang, J.Y., Yan, H.M., PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. Virol. Sin. 26 (2011), 81–94.
6. Li, J.R., Application of rabies vaccine and human rabies immunoglobulin in Fujian Strait. J. Prev. Med. 20 (2014), 79–81.
7. Lin, H.X., Gontier, C., Saron, M.F., Perrin, P., A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects. Arch. Virol. 131 (1993), 307–319.
8. Liu, H., Huang, G., Tang, Q., Li, J., Cao, S., Fu, C., Cao, Q., Liu, B., Pan, H., Wang, M., The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum. Vaccines 7 (2011), 220–224.
9. Manning, S.E., Rupprecht, C.E., Fishbein, D., Hanlon, C.A., Lumlertdacha, B., Guerra, M., Meltzer, M.I., Dhankhar, P., Vaidya, S.A., Jenkins, S.R., Sun, B., Hull, H.F., Human Rabies Prevention-United States, 2008: Recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and Reports, 57, 2008, Centers for Disease Control, 1–28.
10. Saraya, A., Wacharapluesadee, S., Khawplod, P., Tepsumethanon, S., Briggs, D., Asawavichienjinda, T., Hemachudha, T., A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens. Vaccine 28 (2010), 4553–4557.
11. Servat, A., Lutsch, C., Delore, V., Lang, J., Veitch, K., Cliquet, F., Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model. Vaccine 22 (2003), 244–249.
12. Su, K., Xia, Y., Xiao, D.Y., Zhao, H., Long, J., Li, Q., Analysis on the rabies exposure and post-exposure prophylaxis of humane rabies in Chongqing. Mod. Prev. Med. 42 (2015), 548–551.
13. The, L., Time to eliminate rabies. Lancet, 386, 2015, 2446.
14. Uwanyiligira, M., Landry, P., Genton, B., de Valliere, S., Rabies Postexposure Prophylaxis in Routine Practice in View of the New Centers for Disease Control and Prevention and World Health Organization Recommendations, 55, 2012, Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 201–205.
15. Wang, S.S., A new PIKA adjuvant rabies vaccine. J. Appl. Prev. Med. 16 (2010), 1–4.
16. Wiedeman, J., Plant, J., Glaser, C., Messenger, S., Wadford, D., Fritz, C., Lindsay, A., McKenzie, M., Hammond, C., Gordon, E., Rupprecht, C., Petersen, B., Recovery of a Patient from Clinical Rabies-California 2011. MMWR. Morbidity and mortality weekly report, 61, 2012, 61–65.
17. World Health, O., WHO Expert Consultation on Rabies. Second Report., 2013, World Health Organization technical report series, 1–139 (back cover).
18. Yin, W., Dong, J., Tu, C., Edwards, J., Guo, F., Zhou, H., Yu, H., Vong, S., Rabies, T., Advisory, B., Challenges and needs for China to eliminate rabies. Infect. Dis. Poverty, 2, 2013, 23.
19. Yu, Z., Cheng, K., Sun, W., Xin, Y., Cai, J., Ma, R., Zhao, Q., Li, L., Huang, J., Sang, X., Li, X., Zhang, K., Wang, T., Qin, C., Qian, J., Gao, Y., Xia, X., Lowly pathogenic avian influenza (H9N2) infection in Plateau pika (Ochotona curzoniae), Qinghai Lake, China. Vet. Microbiol. 173 (2014), 132–135.
20. Zhang, P., Wu, S., Li, L., Liang, Z., Li, Y., Feng, L., Huang, X., Adjuvant PIKA protects hepatoma cells from dengue virus infection by promoting a TBK-1-dependent innate immune response. Arch. Virol. 158 (2013), 829–838.
21. Zhang, Y., Zhang, S., Li, W., Hu, Y., Zhao, J., Liu, F., Lin, H., Liu, Y., Wang, L., Xu, S., Hu, R., Shao, H., Li, L., A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies. Virology 489 (2016), 165–172.